Epidemiology of acute liver failure

被引：132

作者：

Khashab M. ^{[1
]}

Tector A.J. ^{[1
]}

Kwo P.Y. ^{[1
]}

机构：

[1] Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202

来源：

Current Gastroenterology Reports | 2007年 / 9卷 / 1期

关键词：

Imatinib; International Normalize Ratio; Transjugular Intrahepatic Portosystemic Shunt; Orlistat; Acute Liver Failure;

D O I：

10.1007/s11894-008-0023-x

中图分类号：

学科分类号：

摘要：

Acute liver failure (ALF) is an uncommon disorder that leads to jaundice, coagulopathy, and multisystem organ failure. Its definition is based on the timing from onset of jaundice to encephalopathy. In 2005, ALF accounted for 6% of liver-related deaths and 7% of orthotopic liver transplants (OLT) in the United States. Several classification systems have been developed for ALF, with the King's College criteria most widely used for prediction of OLT. Specific diagnostic tests should be implemented to identify the cause of ALF, which will help to determine its treatment and prognosis. Viral hepatitis was previously reported to be the most common cause of ALF in the United States, but acetaminophen overdose and idiosyncratic drug reactions have emerged as the most frequent causes in recent studies. Malignancy is an uncommon cause of ALF, and thus imaging studies may not be useful in this setting, but liver biopsy may be beneficial in selected cases. An overall strategy for ALF should start with identifying the cause, assessing the prognosis, and early transfer to a transplantation center for suitable candidates. OLT has emerged as a life-saving procedure leading to marked improvement in survival rates. Improved surgical techniques, immunosuppression, and comprehensive care have led to an overall survival rate of approximately 65% with OLT. N-acetylcysteine is effective in ALF caused by acetaminophen overdose, with results strongly related to how soon it is given rather than the route of administration. Liver support systems show potential for the treatment of ALF, but their role needs validation in large multicenter randomized trials. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：66 / 73

页数：7

共 53 条

[1]

Rakela J., Lange S.M., Ludwig J., Baldus W.P., Fulminant hepatitis: Mayo Clinic experience with 34 cases, Mayo Clin Proc, 60, pp. 289-292, (1985)

[2]

Ostapowicz G., Fontana R.J., Schiodt F.V., Et al., Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States, Ann Intern Med, 137, pp. 947-954, (2002)

[3]

Hoofnagle J.H., Carithers R.L.J., Shapiro C., Ascher N., Fulminant hepatic failure: Summary of a workshop, Hepatology, 21, pp. 240-252, (1995)

[4]

Sakaida I., Kimura T., Yamasaki T., Et al., Cytochrome c is a possible new marker for fulminant hepatitis in humans, J Gastroenterol, 40, pp. 179-185, (2005)

[5]

Hiraoka A., Horiike N., Akbar S.M., Et al., Soluble CD163 in patients with liver diseases: Very high levels of soluble CD163 in patients with fulminant hepatic failure, J Gastroenterol, 40, pp. 52-56, (2005)

[6]

Miyake Y., Sakaguchi K., Iwasaki Y., Et al., New prognostic scoring model for liver transplantation in patients with non-acetaminophen-related fulminant hepatic failure, Transplantation, 80, pp. 930-936, (2005)

[7]

Arai M., Yokosuka O., Kanda T., Et al., Serum osteopontin levels in patients with acute liver dysfunction, Scand J Gastroenterol, 41, pp. 102-110, (2006)

[8]

Bernal B., Changing patterns of causation and the use of transplantation in the United Kingdom, Semin Liver Dis, 23, pp. 227-237, (2003)

[9]

Polard E., Camus C., Abault A.Y., Et al., Retransplantation for acute liver failure due to combined antiviral agents in an HIV-HCV coinfected liver transplant recipient, Transplantaton, 80, pp. 1136-1138, (2005)

[10]

Lewis W., Day B.J., Copeland W.C., Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective, Nat Rev Drug Discov, 2, pp. 812-822, (2003)

← 1 2 3 4 5 6 →